Physician profile
Peter Gottlieb
NPI 1750320388
$12,143.31
in general payments reported to CMS, 2019-2025
39 companies · $2,977 in 2025
The $2,977 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $1,203 · 2021: $1,159 · 2022: $1,685 · 2023: $1,794 · 2024: $2,399 · 2025: $2,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,171.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,076.00 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,874.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $1,097.85 | 2020-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,033.48 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Genzyme Corporation | $667.39 | 2021-2025 | |
| Philips North America LLC | $632.43 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Pfizer INC. | $361.44 | 2019-2025 | |
| Amgen INC. | $315.44 | 2021-2025 | Tezspire |
| Insmed, INC. | $279.53 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $169.03 | 2022-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $162.61 | 2019-2021 | |
| Baxter Healthcare | $159.93 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $144.03 | 2022-2024 | Tyvaso |
| Optinose US, INC. | $110.41 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $104.42 | 2023-2025 | Opsumit |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gottlieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.